Interviews

INSIGHT tests if NSCLC super-responders with pathologic complete response can skip adjuvant durvalumab, reducing toxicity without sacrificing survival.

Heather J. Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Community oncology prepares for routine genetic testing, building workflows, training and follow-up to expand hereditary cancer risk care and reduce disparities.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

Young women with lung cancer face stigma, misdiagnosis, trial underrepresentation, and missed fertility support—clinical gaps that delay care and worsen long-term outcomes.

Glioblastoma treatment still stalls beyond Stupp, while meningioma lacks systemic salvage options; Singh highlights adaptive trials, molecular profiling, and young-patient quality-of-life risks.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.

How young women with lung cancer face stigma, misdiagnosis, and fertility gaps—plus the equity-driven approach reshaping care and trials.

MD Anderson trial uses psilocybin-assisted therapy to help head and neck cancer patients cope with trauma and improve recovery.

Andrew Spencer, MBBS, discusses how the inMMyCar trial is finding promise for in vivo CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

Johannes Schetelig, MD, MSc, discusses findings on graft-vs-host disease prophylaxis in unrelated donor allogeneic stem cell transplants.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

ASCO 2026 highlights: KRAS signals, ADC‑immunotherapy momentum, and new TNBC/HER2 breakthroughs shaping next breast cancer trials.